21.94
-0.90 (-3.94%)
| Penutupan Terdahulu | 22.84 |
| Buka | 22.60 |
| Jumlah Dagangan | 392,501 |
| Purata Dagangan (3B) | 461,806 |
| Modal Pasaran | 813,879,424 |
| Harga / Jualan (P/S) | 9.05 |
| Harga / Buku (P/B) | 4.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -62.50% |
| Margin Operasi (TTM) | -69.33% |
| EPS Cair (TTM) | -1.25 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 42.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 12.03% |
| Nisbah Semasa (MRQ) | 17.36 |
| Aliran Tunai Operasi (OCF TTM) | -36.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -26.02 M |
| Pulangan Atas Aset (ROA TTM) | -17.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | CeriBell, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| % Dimiliki oleh Orang Dalam | 10.54% |
| % Dimiliki oleh Institusi | 84.45% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Yu Fan | 30 Sep 2025 | 1,353,166 |
| Abg-Wtt Global Life Science Capital Partners Gp Ltd | 30 Sep 2025 | 1,088,101 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (BTIG, 36.74%) | Beli |
| 30.00 (Canaccord Genuity, 36.74%) | Beli | |
| Median | 30.00 (36.74%) | |
| Purata | 30.00 (36.74%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 21.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 28 Jan 2026 | 30.00 (36.74%) | Beli | 20.55 |
| 15 Dec 2025 | 30.00 (36.74%) | Beli | 21.90 | |
| Canaccord Genuity | 17 Dec 2025 | 30.00 (36.74%) | Beli | 21.59 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Jan 2026 | Pengumuman | Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution |
| 30 Dec 2025 | Pengumuman | Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 09 Dec 2025 | Pengumuman | Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution |
| 24 Nov 2025 | Pengumuman | Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates |
| 19 Nov 2025 | Pengumuman | Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 06 Nov 2025 | Pengumuman | Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |